Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by ScienceFirston Aug 28, 2023 9:06am
263 Views
Post# 35607825

RE:Interview with Roger Dumoulin-White

RE:Interview with Roger Dumoulin-White

Eoganacht ... Excellent catch regarding this additional visibility (dated if August 26).

Looks like our usual grumbler whined too early once again and will say that it's not sufficient enough and that we're all yes men because we don't panic like him!  


Of course, things are never evolving fast enough.  But Welch reached key milestones that allowed us to enter the commercialization stage.  So we're getting there and will get there, with a positive outcome.  Processes (FDA Breakthrough application and jv discussions) have been announced, initiated and are on-going.  TLT has done what it had to do.  Some lack understanding of how complex and slow are those processes but we have no way to doubt that we will get there.

Just to sign a jv deal, Ferrings took 9 months, from the moment it was officially granted FDA commercialization, despite 2y of delays caused by manufacturing issues.  TLT won't have such manufacturing issues because of the nature of our molecule.  And we will strike a jv deal before full commercialization.

Ferring got 500M$ (200M$ + 300M$) in exchange of 5-8% royalties for the US market.  It will be interesting to see how much higher we get.  Makes me think that major pharmas left FERRING's ADSTILADRIN to an obscured (less known) pharma (Royalty Pharma).  Hopefully because they see a much bigger potential with our treatment.

Merck clearly seems to be the partner of ImmunityBio because of ImmunityBio's N-803 has been trial with BCG and is also being trialed with Keytruda.

 

<< Previous
Bullboard Posts
Next >>